Is Caris Life Sciences Inc (CAI) a risky stock?
As of July 27, 2026, Clavix grades Caris Life Sciences Inc (CAI) B- for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts CAI in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
The five risk dimensions behind CAI's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CAI scores on each, as of July 27, 2026.
What's moving CAI's risk right now
Company-specific signals Clavix flags behind CAI's current grade, drawn from recent news and filings as of July 27, 2026.
Caris launched Caris Detect, a blood test designed to screen for multiple cancers early. The product opens a new revenue line in the fast-growing liquid biopsy market and could boost the company's top line.
A company director purchased nearly $1 million in shares, a move typically read as insider confidence. Separately, Caris scheduled its second-quarter 2026 earnings release for August 5.
Caris expanded its precision oncology lineup with in-house PTEN IHC testing tied to a newly approved prostate cancer drug. The move could generate companion diagnostic revenue and reinforce the company's oncology franchise.
Recent CAI news
The latest headlines Clavix ingested for Caris Life Sciences Inc, newest first. These feed the news-sentiment dimension of CAI's grade.
-
Caris Life Sciences (CAI) stock has declined 47.3% over the past 12 months, yet valuation metrics suggest the stock is undervalued relative to its fundamentals. The company has launched new products including the Caris Detect multi-cancer screening test and an in-house PTEN IHC testing offering.
What a B- grade means
On the Clavix A+ to F scale, CAI's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CAI or any security. Grades are risk indicators, not predictions of return. Data may be delayed.